Browsing Tag
Sanofi
75 posts
Dupixent keeps winning trials—but can it survive the real battle with payers?
Explore how payer dynamics and pricing strategy may pose the biggest challenge for Dupixent’s growth, beyond clinical trials or biologic competitors.
Breakthrough REZOLVE-AD results position Rezpegaldesleukin as a potential first-in-class IL-2 Treg therapy for atopic dermatitis and asthma
Rezpegaldesleukin delivers strong dual skin and asthma results in the REZOLVE-AD study — find out how Nektar Therapeutics plans to advance its IL-2 Treg platform in 2026.
Is Dupixent now the gold standard for asthma with nasal polyps? Inside Sanofi and Regeneron’s big study win
Dupixent outperforms Xolair in phase 4 respiratory trial for chronic rhinosinusitis with asthma. Find out what this means for Sanofi and Regeneron’s growth.
Regeneron’s Libtayo wins FDA approval as first adjuvant immunotherapy for high-risk skin cancer patients
Find out how Regeneron’s Libtayo is redefining skin cancer care as the first FDA-approved adjuvant immunotherapy for high-risk CSCC patients
Sanofi taps Novavax’s Matrix-M for flu: Is NVAX stock finally turning a corner?
Novavax (NASDAQ: NVAX) expands Sanofi partnership, granting rights to Matrix-M adjuvant for pandemic flu candidates. See stock impact and outlook.
How recombinant therapies are reshaping bleeding disorder treatment for children in 2025
Recombinant therapies are replacing plasma-derived treatments for pediatric bleeding disorders—see what’s driving this shift in 2025 and who’s leading.
Daiichi Sankyo launches development of oral triple combination tablets for LDL cholesterol management in Europe
Daiichi Sankyo (TYO: 4568) begins developing oral triple therapy with bempedoic acid, ezetimibe, and statins to transform LDL cholesterol management in Europe.
Unisom partners with Julian Edelman to tackle fantasy football stress with sleep-first strategy
Unisom joins forces with Julian Edelman to launch Sleeper Pickz, linking fantasy football advice with better sleep. Find out how this campaign redefines rest.
Can Sanofi turn molecular clamp technology into a global respiratory vaccine platform beyond RSV?
Can Sanofi turn Vicebio’s molecular clamp tech into a global respiratory vaccine platform? Analysts see multi-pathogen potential beyond RSV by 2030.
How much could Vicebio’s $1.15bn acquisition add to Sanofi’s RSV market share by 2030?
Can Sanofi’s $1.15B Vicebio deal help it win 10% of the RSV market by 2030? Analysts weigh in on how combination vaccines could change respiratory care.